Shopping Cart
Remove All
Your shopping cart is currently empty
Anti-TNFRSF7/CD27 Antibody
Copy Product Info
🥰Excellent
Synonyms:
Catalog No. T9901A-1342 Copy Product Info
🥰Excellent
Anti-TNFRSF7/CD27 Antibody (Varlilumab) is a humanized agonistic monoclonal antibody targeting CD27 (TNFRSF7). This product specifically binds to the CD27 receptor on T cells, mimicking the costimulatory signal of the CD70 ligand and triggering the activation of the NF-kappaB signaling pathway. This action enhances the activation, proliferation, and cytokine secretion (such as IFN-gamma) of antigen-specific T cells. In preclinical models, the antibody induces potent anti-tumor immune responses; in clinical studies, combination with PD-1 inhibitors modulates the immune microenvironment and increases circulating chemokine levels.
Anti-TNFRSF7/CD27 Antibody
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $377 | Inquiry | Inquiry |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Antibody Information
Storage & Solubility Information
| Description | Anti-TNFRSF7/CD27 Antibody (Varlilumab) is a humanized agonistic monoclonal antibody targeting CD27 (TNFRSF7). This product specifically binds to the CD27 receptor on T cells, mimicking the costimulatory signal of the CD70 ligand and triggering the activation of the NF-kappaB signaling pathway. This action enhances the activation, proliferation, and cytokine secretion (such as IFN-gamma) of antigen-specific T cells. In preclinical models, the antibody induces potent anti-tumor immune responses; in clinical studies, combination with PD-1 inhibitors modulates the immune microenvironment and increases circulating chemokine levels. |
| In vitro | In T-cell assays, Anti-TNFRSF7/CD27 Antibody acts as an agonist to trigger NF-kappaB signaling, enhancing T-cell receptor-mediated proliferation and the production of IFN-gamma and IL-2. In patient-derived samples, treatment increases activation markers on CD8+ T cells and elevates CXCL9/10 levels [1][2]. |
| In vivo | In pharmacological studies using human CD27-transgenic mouse models, systemic administration of Anti-TNFRSF7/CD27 Antibody (at doses such as 0.1-10 mg/kg) results in significant regression of established tumors and long-term protective immunity.[1][2] |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID | |
| Target | TNFRSF7/CD27 |
| Isotype | IgG2SA |
| Storage | Store at low temperature Store at -20°C Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: Anti-TNFRSF7/CD27 Antibody in vivo | Anti-TNFRSF7/CD27 Antibody in vitro
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.